Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s room for many MASH drugs with the treatment landscape expected to shape up to include combinations of therapies bringing different approaches to this fatty liver disease.
The post FDA Approval Expands Novo Nordisk’s Wegovy to the Fatty Liver Disease MASH appeared first on MedCity News.
